Ballicules.com

Methenamine mandelate

MANDELAMINE

Methenamine mandelate ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Methenamine mandelate ballicule

What it isConverted to formaldehyde in acidic urine; recurrent urinary infection prophylaxis.

Why this oneIts mandelic-acid component adds antibacterial action and helps acidify urine beyond formaldehyde release.

What limits itIt works only in acidic urine and is prophylaxis, not treatment; avoid with sulfonamides and carbonic anhydrase inhibitors.

Methenamine mandelate molecular structure (skeletal formula)
Molecular structure: Methenamine mandelate

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
UTI — prophylaxis/suppressionAdults1 g QID (after each meal and at bedtime)4 g/day (1 × 1000 mg tab or 2 × 500 mg tabs QID)4 g/day
UTI — prophylaxis/suppressionChildren 6–12 yr500 mg QID (half the adult dose)2 g/day2 g/day

Renal Contraindicated in renal insufficiency.

Hepatic Contraindicated in severe hepatic disease.

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Category C — crosses the placenta; use only if potential benefit outweighs risk.

Lactation Undefined

Cost

Methenamine mandelate (MANDELAMINE)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
500 mgtab120 QID$163.31not offered
1000 mgtab120 QID$312.52not offered

Generic entryPre-1982

NO BOXED WARNINGS

Principal riskIt needs urine pH below 6; prophylaxis only

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Methenamine mandelate in the interactive console ↗